ANTI-SLC6A6 ANTIBODY AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT INCLUDING SAID ANTIBODY

摘要

The present invention relates to the provision of a new pharmaceutical composition that is cancer-specific and has few side effects. The present invention provides a pharmaceutical composition including a monoclonal antibody that has higher affinity than conventional antibodies and can recognize native SLC6A6 or a polypeptide of an extracellular domain of SLC6A6.